Department of Internal Medicine III, University Hospital RWTH Aachen, Aachen, Germany.
Nutrition, Metabolism and Genomics group, Division of Human Nutrition, Wageningen University, Wageningen, the Netherlands.
Cancer Res. 2015 Mar 15;75(6):1144-55. doi: 10.1158/0008-5472.CAN-14-1356. Epub 2015 Jan 21.
Genetic mouse studies suggest that the NF-κB pathway regulator NEMO (also known as IKKγ) controls chronic inflammation and carcinogenesis in the liver. However, the molecular mechanisms explaining the function of NEMO are not well defined. Here, we report that overexpression of the cell-cycle regulator p21 is a critical feature of liver inflammation and carcinogenesis caused by the loss of NEMO. NEMO(Δhepa) mice develop chronic hepatitis characterized by increased hepatocyte apoptosis and proliferation that causes the development of fibrosis and hepatocellular carcinoma (HCC), similar to the situation in human liver disease. Having identified p21 overexpression in this model, we evaluated its role in disease progression and LPS-mediated liver injury in double mutant NEMO(Δhepa)/p21(-/-) mice. Eight-week-old NEMO(Δhepa)/p21(-/-) animals displayed accelerated liver damage that was not associated with alterations in cell-cycle progression or the inflammatory response. However, livers from NEMO(Δhepa)/p21(-/-) mice displayed more severe DNA damage that was further characterized by LPS administration correlating with higher lethality of the animals. This phenotype was attenuated by genetic ablation of the TNF receptor TNF-R1 in NEMO(Δhepa)/p21(-/-) mice, demonstrating that DNA damage is induced via TNF. One-year-old NEMO(Δhepa)/p21(-/-) mice displayed greater numbers of HCC and severe cholestasis compared with NEMO(Δhepa) animals. Therefore, p21 overexpression in NEMO(Δhepa) animals protects against DNA damage, acceleration of hepatocarcinogenesis, and cholestasis. Taken together, our findings illustrate how loss of NEMO promotes chronic liver inflammation and carcinogenesis, and they identify a novel protective role for p21 against the generation of DNA damage.
遗传小鼠研究表明,NF-κB 通路调节剂 NEMO(也称为 IKKγ)控制肝脏的慢性炎症和癌变。然而,解释 NEMO 功能的分子机制尚不清楚。在这里,我们报告细胞周期调节剂 p21 的过表达是由 NEMO 缺失引起的肝脏炎症和癌变的关键特征。NEMO(Δhepa) 小鼠发生慢性肝炎,其特征为肝细胞凋亡和增殖增加,导致纤维化和肝细胞癌(HCC)的发展,类似于人类肝脏疾病的情况。在该模型中鉴定出 p21 的过表达后,我们评估了其在疾病进展和 LPS 介导的肝损伤中的作用在双突变 NEMO(Δhepa)/p21(-/-) 小鼠中。八周龄的 NEMO(Δhepa)/p21(-/-) 动物表现出加速的肝损伤,与细胞周期进程或炎症反应的改变无关。然而,NEMO(Δhepa)/p21(-/-) 小鼠的肝脏显示出更严重的 DNA 损伤,进一步用 LPS 给药进行了特征描述,与动物的更高死亡率相关。这种表型在 NEMO(Δhepa)/p21(-/-) 小鼠中通过 TNF 受体 TNF-R1 的基因缺失得到减弱,表明 DNA 损伤是通过 TNF 诱导的。与 NEMO(Δhepa) 动物相比,一岁的 NEMO(Δhepa)/p21(-/-) 小鼠显示出更多的 HCC 和严重的胆汁淤积。因此,NEMO(Δhepa) 动物中 p21 的过表达可防止 DNA 损伤、加速肝癌发生和胆汁淤积。总之,我们的研究结果说明了 NEMO 的缺失如何促进慢性肝脏炎症和癌变,并确定了 p21 对 DNA 损伤产生的新的保护作用。